AZD0901 bij deelnemers met geavanceerde solide tumoren die Claudin tot expressie brengen18.2
Een fase II, open-label, multicenter onderzoek om de veiligheid, verdraagbaarheid, werkzaamheid, PK en immunogeniciteit van AZD0901 als monotherapie en in combinatie met antikankermiddelen te evalueren bij deelnemers met gevorderde solide tumoren die Claudin tot expressie brengen 18.2.
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This open-label, multi-centre study consists of individual sub studies, each evaluating the safety and tolerability of AZD0901.
Sub study 1 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic gastric esophageal cancer expressing CLDN18.2. Participants will receive AZD0901 monotherapy via intravenous (IV) infusion and will be randomised in to one of 2 arms.
Sub study 2 will consist of two parts, a safety run-in and a dose expansion part to investigate the safety and efficacy of AZD0901 in combination with different chemotherapy agents in participants with pancreatic cancer. Substudy 3 will investigate the safety, tolerability, and anti-tumour activity of AZD0901 monotherapy in participants with advanced or metastatic Biliary tract cancer.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: AstraZeneca Clinical Study Information Center
- Telefoonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studie Locaties
-
-
-
Melbourne, Australië, 3000
- Werving
- Research Site
-
Murdoch, Australië, WA6150
- Werving
- Research Site
-
Randwick, Australië, 2031
- Werving
- Research Site
-
-
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Ingetrokken
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Werving
- Research Site
-
Sherbrooke, Quebec, Canada, J1G 2E8
- Werving
- Research Site
-
-
-
-
-
Changsha, China, 410013
- Nog niet aan het werven
- Research Site
-
Chengdu, China, 610041
- Nog niet aan het werven
- Research Site
-
-
-
-
-
Tbilisi, Georgië, 0112
- Werving
- Research Site
-
-
-
-
-
Chūōku, Japan, 104-0045
- Werving
- Research Site
-
Kashiwa, Japan, 227-8577
- Werving
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Werving
- Research Site
-
Kōtoku, Japan, 135-8550
- Werving
- Research Site
-
Nagoya, Japan, 464-8681
- Werving
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Werving
- Research Site
-
-
-
-
-
George Town, Maleisië, 10450
- Werving
- Research Site
-
Johor Bahru, Maleisië, 81100
- Voltooid
- Research Site
-
Kuala Lumpur, Maleisië, 59100
- Werving
- Research Site
-
Kuala Selangor, Maleisië, 62250
- Werving
- Research Site
-
Kuching, Maleisië, 93586
- Werving
- Research Site
-
-
-
-
-
Chisinau, Moldavië, MD-2025
- Werving
- Research Site
-
-
-
-
-
Krakow, Polen, 31-501
- Werving
- Research Site
-
Warsaw, Polen, 02-034
- Werving
- Research Site
-
-
-
-
-
Bukit Merah, Singapore, 169610
- Werving
- Research Site
-
Singapore, Singapore, 308433
- Werving
- Research Site
-
Singapore, Singapore, 119074
- Werving
- Research Site
-
Singapore, Singapore, 329563
- Werving
- Research Site
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Research Site
-
Madrid, Spanje, 28007
- Werving
- Research Site
-
Madrid, Spanje, 28040
- Werving
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Werving
- Research Site
-
Taichung, Taiwan, 404
- Werving
- Research Site
-
Tainan, Taiwan, 70403
- Werving
- Research Site
-
Taipei, Taiwan, 11217
- Werving
- Research Site
-
Taoyuan, Taiwan, 00333
- Werving
- Research Site
-
-
-
-
-
Glasgow, Verenigd Koninkrijk, G12 0YN
- Ingetrokken
- Research Site
-
Leeds, Verenigd Koninkrijk, LS9 7TF
- Ingetrokken
- Research Site
-
London, Verenigd Koninkrijk, NW3 2QG
- Ingetrokken
- Research Site
-
Oxford, Verenigd Koninkrijk, OX3 7LE
- Ingetrokken
- Research Site
-
-
-
-
California
-
Orange, California, Verenigde Staten, 92868
- Werving
- Research Site
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Research Site
-
Santa Rosa, California, Verenigde Staten, 95403
- Werving
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- Research Site
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Werving
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Werving
- Research Site
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Research Site
-
-
-
-
-
Gyeonggi-do, Zuid -Korea, 13620
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03080
- Werving
- Research Site
-
Seoul, Zuid -Korea, 06351
- Werving
- Research Site
-
Seoul, Zuid -Korea, 05505
- Werving
- Research Site
-
Seoul, Zuid -Korea, 03722
- Werving
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria.
Master Inclusion Criteria applicable to all sub studies:
- Participant must be ≥ 18 years or the legal age of consent at the time of signing the ICF.
- Participants who are CLDN18.2 positive.
- Must have at least one measurable lesion according to RECIST v1.1.
- ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.
- Predicted life expectancy of ≥ 12 weeks.
- Adequate organ and bone marrow function as defined by protocol.
- Body weight > 35 kg.
- Participants are willing to comply with contraception requirements.
Sub study 1 Specific Inclusion criteria:
- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.
- Advanced or metastatic GC/GEJC.
- Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Sub study 2 Specific Inclusion criteria:
- Participants diagnosed with histologically confirmed metastatic or advanced PDAC.
- Availability of an archival sample or a fresh tumour biopsy taken at screening.
- No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed ≥ 6 months (183 days) from the last dose.
Sub study 3 Specific Inclusion criteria
- Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).
- Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Master Exclusion Criteria applicable to all sub studies:
- Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
- Participants with clinically significant ascites that require drainage.
- A history of drug-induced non-infectious ILD/pneumonitis.
- Central nervous system metastases or CNS pathology.
- Peripheral neuropathy, sensory, or motor ≥ Grade 2 at screening.
- History of another primary malignancy.
- Prior exposure to any MMAE-based ADC.
- Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody.
Sub study 1 Specific Exclusion criteria:
- Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
- The use of concomitant medications known to prolong the QT/QTc interval.
Sub study 2 Specific Exclusion criteria:
- Known DPD enzyme deficiency based on local testing where testing is SoC.
- Use of strong inhibitor or inducer of UGT1A1.
- Use of strong inhibitors or inducers of CYP3A4.
- Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC.
Sub study 3 Specific Exclusion criteria
• Clinically significant biliary obstruction that has not resolved before enrollment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Sub Study 1 - AZD0901 MONOTHERAPY
Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901. |
Antibody-drug conjugate/Biologic
Andere namen:
|
|
Experimenteel: Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC DUCTAL ADENOCARCINOMA
Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents |
Antibody-drug conjugate/Biologic
Andere namen:
Chemotherapy agents
Andere namen:
Chemotherapy agents
Andere namen:
Chemotherapy agents
Andere namen:
Chemotherapy agents
Andere namen:
Chemotherapy agents
Andere namen:
Chemotherapy agents
Andere namen:
|
|
Experimenteel: Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER
Substudy 3 Further evaluate the preliminary anti-tumour activity of AZD0901 monotherapy by assessment of DRR. |
Antibody-drug conjugate/Biologic
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
Tijdsspanne: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
|
To investigate the safety and tolerability, of AZD0901 monotherapy or in combination with anti-cancer agents in particpants with advanced or metastatic solid tumours expressing CLDN18.2. |
30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
|
|
Objective Response Rate (ORR).
Tijdsspanne: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
|
Proportion of participants with a confirmed Complete Response (CR) or Partial Response (PR) as determined by the Investigator at local site as per RECIST v1.1. |
From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival (OS)
Tijdsspanne: From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
|
The analysis will include all dosed/randomised participants as assigned/randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy. |
From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
|
|
Progression Free Survival (PFS)
Tijdsspanne: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
|
Progression-free survival is defined as the time date of randomisation or enrollment until progression per RECIST v1.1 as assessed by the Investigator at local site, or death due to any cause, regardless of whether the participant withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression. |
From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
|
|
Duration of Response (DoR)
Tijdsspanne: From the date of first documented confirmed response until date of documented progression (approximately 2 years).
|
The time from the date of first documented confirmed response until date of first documented progression per RECIST v1.1 or death due to any cause. |
From the date of first documented confirmed response until date of documented progression (approximately 2 years).
|
|
Disease control rate (DCR)
Tijdsspanne: Up to 11 weeks post date of first dose/randomisation
|
The percentage of participants who have a confirmed CR or PR or who have SD per RECIST v1.1 as assessed by the Investigator at local site and derived from the raw tumour data up to 11 weeks after date of first dose/randomisation. |
Up to 11 weeks post date of first dose/randomisation
|
|
Percentage change in tumor size
Tijdsspanne: From start through to study completion.
|
The best percentage change from baseline in tumor size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments. |
From start through to study completion.
|
|
Serum concentration of AZD0901 (total ADC), total antibody (conjugated and unconjugated) and total unconjugated MMAE
Tijdsspanne: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
|
Serum PK parameters of AZD0901, total antibody (conjugated and unconjugated) and MMAE including but not limited to AUC, Cmax, tmax, clearance and half-life, as data allow.
Tijdsspanne: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
|
Clinical activity by baseline and/or on-treatment tissue-based biomarkers including, but not limited to, gene expression, mutation profiles, DNA damage, protein expression, immune response and/or mechanisms of resistance.
Tijdsspanne: From date of first dose of AZD0901 up to 7 weeks.
|
To investigate baseline and/or on-treatment tissue-based RNA, DNA, and/or proteins, and association with clinical activity of AZD0901 (substudy 1). |
From date of first dose of AZD0901 up to 7 weeks.
|
|
ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established.
Tijdsspanne: From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
To determine the immunogenicity of AZD0901 monotherapy or in combination with anti-cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2. |
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Maag Ziekten
- Ziekten van de galwegen
- Maagneoplasmata
- Neoplasmata van de galwegen
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Camptothecin
- Alkaloïden
- Enzymen en co -enzymen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolaten
- Foliumzuur
- Pterins
- Pteridines
- Uracil
- Pyrimidinonen
- Co -enzymen
- Irinotecan
- Gemcitabine
- Fluorouracil
- Leucovorin
- irinotecan sucrosofaat
Andere studie-ID-nummers
- D9800C00001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .